Posted September 23, 2019
Wang W, Erbe AK, Gallenberger M, Kim KM, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng S-C, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532.